PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screening in Newborns

PerkinElmer, Inc. announced that the FDA had authorized the marketing of the EONI™ SCID-SMA assay kit for in vitro diagnostic use by certified laboratories for the simultaneous detection of spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns.